Literature DB >> 19211507

Paradoxical effects of IFN-gamma in graft-versus-host disease reflect promotion of lymphohematopoietic graft-versus-host reactions and inhibition of epithelial tissue injury.

Hui Wang1, Wannee Asavaroengchai, Beow Yong Yeap, Min-Guang Wang, Shumei Wang, Megan Sykes, Yong-Guang Yang.   

Abstract

Interferon-gamma (IFN-gamma) inhibits graft-versus-host disease (GVHD) in lethally irradiated mice receiving allogeneic hematopoietic cell transplantation (allo-HCT) but promotes lethality in unirradiated and sublethally irradiated recipients. We investigated the role of IFN-gamma in GVHD in sublethally irradiated B6D2F1 recipients of B6 allo-HCT. B6D2F1 mice receiving wild-type B6 splenocytes alone died rapidly, whereas those receiving wild-type B6 splenocytes plus marrow survived long-term. Mice in both groups showed rapid elimination of host hematopoietic cells but minimal parenchymal tissue injury. However, mice receiving allo-HCT from IFN-gamma-deficient donors died rapidly regardless of whether donor marrow was given, and they exhibited severe parenchymal injury but prolonged survival of host hematopoietic cells. IFN-gamma plays a similar role in another model involving delayed B6 donor leukocyte infusion (DLI) to established mixed allogeneic (B6-->BALB/c) chimeras. IFN-gamma promotes DLI-mediated conversion from mixed to full donor chimerism while attenuating GVHD. Importantly, IFN-gamma enhances graft-versus-leukemia (GVL) effects in both models. Our data indicate that previously reported IFN-gamma-induced early mortality in allo-HCT recipients is due to augmentation of lymphohematopoietic graft-versus-host reaction (LGVHR) and can be avoided by providing an adequate source of donor hematopoietic stem/progenitor cells. Furthermore, the magnitude of GVL is correlated with the strength of LGVHR, and IFN-gamma reduces the potential of this alloreactivity to cause epithelial tissue GVHD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19211507      PMCID: PMC2668848          DOI: 10.1182/blood-2008-07-168419

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.

Authors:  T J Sayers; T A Wiltrout; K McCormick; C Husted; R H Wiltrout
Journal:  Cancer Res       Date:  1990-09-01       Impact factor: 12.701

Review 2.  IFN-gamma production by antigen-presenting cells: mechanisms emerge.

Authors:  D M Frucht; T Fukao; C Bogdan; H Schindler; J J O'Shea; S Koyasu
Journal:  Trends Immunol       Date:  2001-10       Impact factor: 16.687

3.  Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells.

Authors:  Yong-Guang Yang; Jin Qi; Min-Guang Wang; Megan Sykes
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

4.  Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production.

Authors:  J Baker; M R Verneris; M Ito; J A Shizuru; R S Negrin
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

5.  Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells.

Authors:  Markus Y Mapara; Yong-Mi Kim; Sheng-Ping Wang; Roderick Bronson; David H Sachs; Megan Sykes
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

6.  Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies.

Authors:  Thomas R Spitzer; Steven L McAfee; Bimalangshu R Dey; Christine Colby; James Hope; Howard Grossberg; Frederic Preffer; Juanita Shaffer; Stephen I Alexander; David H Sachs; Megan Sykes
Journal:  Transplantation       Date:  2003-05-27       Impact factor: 4.939

7.  The anti-tumor effect of recombinant interferon alpha or gamma is influenced by tumor location.

Authors:  M J Brunda; V Sulich; D Bellantoni
Journal:  Int J Cancer       Date:  1987-12-15       Impact factor: 7.396

8.  Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis.

Authors:  P Reddy; T Teshima; M Kukuruga; R Ordemann; C Liu; K Lowler; J L Ferrara
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

9.  Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells.

Authors:  M Sykes; M A Sheard; D H Sachs
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

10.  CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease.

Authors:  José L Cohen; Aurélie Trenado; Douglas Vasey; David Klatzmann; Benoît L Salomon
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

View more
  31 in total

1.  Role of IFN-γ in the establishment of anterior chamber-associated immune deviation (ACAID)-induced CD8+ T regulatory cells.

Authors:  Kathryn Paunicka; Peter W Chen; Jerry Y Niederkorn
Journal:  J Leukoc Biol       Date:  2011-12-16       Impact factor: 4.962

2.  IFN-γ promotes graft-versus-leukemia effects without directly interacting with leukemia cells in mice after allogeneic hematopoietic cell transplantation.

Authors:  Yanping Yang; Hui Wang; Hui Yu; Beow Yong Yeap; Tingting Liang; Guanjun Wang; Tao Cheng; Yong-Guang Yang
Journal:  Blood       Date:  2011-08-11       Impact factor: 22.113

3.  Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.

Authors:  Katelyn Paz; Ryan Flynn; Jing Du; Stacey Tannheimer; Amy J Johnson; Shuai Dong; Anne-Katrien Stark; Klaus Okkenhaug; Angela Panoskaltsis-Mortari; Peter T Sage; Arlene H Sharpe; Leo Luznik; Jerome Ritz; Robert J Soiffer; Corey S Cutler; John Koreth; Joseph H Antin; David B Miklos; Kelli P MacDonald; Geoffrey R Hill; Ivan Maillard; Jonathan S Serody; William J Murphy; David H Munn; Colby Feser; Michael Zaiken; Bart Vanhaesebroeck; Laurence A Turka; John C Byrd; Bruce R Blazar
Journal:  Am J Transplant       Date:  2019-03-19       Impact factor: 8.086

4.  Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice.

Authors:  Huihui Ma; Caisheng Lu; Judith Ziegler; Ailing Liu; Antonia Sepulveda; Hideho Okada; Suzanne Lentzsch; Markus Y Mapara
Journal:  J Clin Invest       Date:  2011-06-13       Impact factor: 14.808

5.  Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses.

Authors:  Christine Vogtenhuber; Christoph Bucher; Steven L Highfill; Lisa K Koch; Emily Goren; Angela Panoskaltsis-Mortari; Patricia A Taylor; Michael A Farrar; Bruce R Blazar
Journal:  Blood       Date:  2010-05-04       Impact factor: 22.113

6.  Altered effector CD4+ T cell function in IL-21R-/- CD4+ T cell-mediated graft-versus-host disease.

Authors:  Iekuni Oh; Katsutoshi Ozaki; Akiko Meguro; Keiko Hatanaka; Masanori Kadowaki; Haruko Matsu; Raine Tatara; Kazuya Sato; Yoichiro Iwakura; Susumu Nakae; Katsuko Sudo; Takanori Teshima; Warren J Leonard; Keiya Ozawa
Journal:  J Immunol       Date:  2010-06-23       Impact factor: 5.422

7.  Activated CD8 T cells acquire NK1.1 expression and preferentially locate in the liver in mice after allogeneic hematopoietic cell transplantation.

Authors:  Yi Wang; Hui Wang; Jinxing Xia; Tingting Liang; Guanjun Wang; Xiaokun Li; Yong-Guang Yang
Journal:  Immunol Lett       Date:  2013-01-03       Impact factor: 3.685

8.  IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity.

Authors:  Ying Lu; Cynthia R Giver; Akshay Sharma; Jian Ming Li; Katarzyna A Darlak; Lauren M Owens; John D Roback; Jacques Galipeau; Edmund K Waller
Journal:  Blood       Date:  2011-11-30       Impact factor: 22.113

9.  Allogeneic Th1 cells home to host bone marrow and spleen and mediate IFNγ-dependent aplasia.

Authors:  Joseph H Chewning; Weiwei Zhang; David A Randolph; C Scott Swindle; Trenton R Schoeb; Casey T Weaver
Journal:  Biol Blood Marrow Transplant       Date:  2013-03-21       Impact factor: 5.742

10.  Graft-versus-host disease depletes plasmacytoid dendritic cell progenitors to impair tolerance induction.

Authors:  Yuanyuan Tian; Lijun Meng; Ying Wang; Bohan Li; Hongshuang Yu; Yan Zhou; Tien Bui; Ciril Abraham; Alicia Li; Yongping Zhang; Jian Wang; Chenchen Zhao; Shin Mineishi; Stefania Gallucci; David Porter; Elizabeth Hexner; Hong Zheng; Yanyun Zhang; Shaoyan Hu; Yi Zhang
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.